[1] Gurevitz SL, Snyder JA, Wessel EK,et al. Systemic lupus erythematosus: a review of the disease and treatment options. Consult Pharm. 2013;28(2):110-121.[2] Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2016 Nov 7. pii: CJN.05780616. [Epub ahead of print] [3] Ruan GP, Yao X, Yang SJ, et al. Transplanted human umbilical cord mesenchymal stem cells facilitate lesion repair in B6.Fas mice.J Immunol Res. 2014;2014:530501.[4] Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2(2):83-92.[5] Klimczak A, Kozlowska U. Mesenchymal Stromal Cells and Tissue-Specific Progenitor Cells: Their Role in Tissue Homeostasis. Stem Cells Int. 2016;2016:4285215.[6] Maji K, Dasgupta S, Kundu B, et al. Development of gelatin-chitosan-hydroxyapatite based bioactive bone scaffold with controlled pore size and mechanical strength. J Biomater Sci Polym Ed. 2015;26(16):1190-1209.[7] El-Badri NS, Hakki A, Ferrari A, et al. Autoimmune disease: is it a disorder of the microenvironment. Immunol Res. 2008; 41(1):79-86.[8] Sun LY, Zhang HY, Feng XB, et al. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus. 2007;16(2):121-128.[9] Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010; 69(8):1423-1429.[10] Tang Y, Ma X, Zhang H, et al. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:826182.[11] Ghannam S, Bouffi C, Djouad F, et al. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 2010;1(1):2.[12] Lu S, Zeumer L, Sorensen H, et al. The murine Pbx1-d lupus susceptibility allele accelerates mesenchymal stem cell differentiation and impairs their immunosuppressive function. J Immunol. 2015;194(1):43-55.[13] Kronsteiner B, Peterbauer-Scherb A, Grillari-Voglauer R, et al. Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell Immunol. 2011;267(1): 30-38.[14] Batten P, Sarathchandra P, Antoniw JW, et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng. 2006;12(8):2263-2273.[15] Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838-3843.[16] Krampera M, Cosmi L, Angeli R, et al. Role for interferon- gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24(2): 386-398.[17] Xu ZJ, Sheng LX, Ouyang GF. Effect of umbilical cord blood mesenchymal stem cells on peripheral blood lymphocyte subsets. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(1): 207-211.[18] Ren G, Zhao X, Zhang L, et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol. 2010;184(5):2321-2328.[19] 李慧,孙凌云.MRUlpr鼠骨髓间充质干细胞对T淋巴细胞作用的研究[J]. 中华风湿病学杂志,2007,11(2):340-343.[20] Danger R, Thervet E, Grisoni ML, et al. PARVG gene polymorphism and operational renal allograft tolerance. Transplant Proc. 2012;44(9):2845-2848.[21] Wang H1, Wu M, Liu Y. Are mesenchymal stem cells major sources of safe signals in immune system. Cell Immunol. 2012;272(2):112-116.[22] Hermankova B, Zajicova A, Javorkova E, et al. Suppression of IL-10 production by activated B cells via a cell contact-dependent cyclooxygenase-2 pathway upregulated in IFN-γ-treated mesenchymal stem cells. Immunobiology. 2016; 221(2):129-136.[23] Sabry A, Sheashaa H, El-Husseini A, et al. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006;35(3-4): 148-153.[24] Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf. 2008;7(4):411-419.[25] Tucci M, Lombardi L, Richards HB, et al. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol. 2008;154(2):247-254.[26] Bai L, Lennon DP, Eaton V, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009; 57(11):1192-1203.[27] Lu X, Liu T, Gu L, et al. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets. Transpl Immunol. 2009;22(1-2):55-61.[28] Wu H, Zhao M, Chang C, et al. The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation. Int J Mol Sci. 2015;16(5):11013-11033.[29] Hayashi T, Hasegawa K, Sasaki Y, et al. Systemic administration of interleukin-4 expressing plasmid DNA delays the development of glomerulonephritis and prolongs survival in lupus-prone female NZB x NZW F1 mice. Nephrol Dial Transplant. 2007;22(11):3131-3138.[30] Chang JW, Hung SP, Wu HH, et al. Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant. 2011;20(2):245-257.[31] Liu W, Morschauser A, Zhang X, et al. Human placenta-derived adherent cells induce tolerogenic immune responses. Clin Transl Immunology. 2014;3(5):e14.[32] Mohammadzadeh A, Pourfathollah AA, Shahrokhi S, et al. Immunomodulatory effects of adipose-derived mesenchymal stem cells on the gene expression of major transcription factors of T cell subsets. Int Immunopharmacol. 2014;20(2): 316-321.[33] Duffy MM, Ritter T, Ceredig R, et al. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther. 2011; 2(4):34.[34] Scheinecker C, Bonelli M, Smolen JS. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun. 2010;35(3):269-275.[35] Hall BM, Tran GT, Verma ND, et al. Do Natural T Regulatory Cells become Activated to Antigen Specific T Regulatory Cells in Transplantation and in Autoimmunity. Front Immunol. 2013; 4:208.[36] Liu Y, Zhang P, Li J, et al. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol. 2008;9(6):632-640.[37] English K, French A, Wood KJ. Mesenchymal stromal cells: facilitators of successful transplantation. Cell Stem Cell. 2010; 7(4):431-442.[38] English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009;156(1):149-160.[39] Gonzalez-Rey E, Gonzalez MA, Varela N, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010; 69(1):241-248.[40] Afzali B, Mitchell P, Lechler RI, et al. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol. 2010;159(2):120-130.[41] Gu Z, Cao X, Jiang J, et al. Upregulation of p16INK4A promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Cell Signal. 2012;24(12):2307-2314.[42] Che N, Li X, Zhou S, et al. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell Immunol. 2012;274(1-2):46-53.[43] Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367-372.[44] Schena F, Gambini C, Gregorio A, et al. Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 2010;62(9): 277627-277686. [45] Rafei M, Hsieh J, Fortier S, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008;112(13):4991-4998.[46] Che N, Li X, Zhang L, et al. Impaired B cell inhibition by lupus bone marrow mesenchymal stem cells is caused by reduced CCL2 expression. J Immunol. 2014;193(10):5306-5314.[47] Traggiai E, Volpi S, Schena F, et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells. 2008; 26(2):562-569.[48] Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity. 2008;28(6):799-809.[49] Parys M. Immunomodulatory properties of feline mesenchymal stem cells and their clinical application in treatment of feline chronic idiopathic cystitis. Michigan State University. 2016; 157:10151286.[50] Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26: 677-704.[51] 聂瑛洁,罗利梅,查艳,等.系统性红斑狼疮患者血浆降低间充质干细胞对B淋巴细胞的抑制作用[J]. 南方医科大学学报,2016, 36(8):1090-1093.[52] Youd M, Blickarz C, Woodworth L, et al. Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol. 2010;1 61(1):176-186.[53] Rosado MM, Bernardo ME, Scarsella M, et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 2015; 24(1):93-103. |